Feature | April 04, 2014

Head-to-Head Study Reports Patient Comfort With Iodixanol, Iopamidol During Peripheral Arteriography

Iodixanol Iopamidol Contrast Media Peripheral Arteriography ACC.14 Clinical Stud

April 4, 2014 — GE Healthcare announced results from a new clinical study, which showed that patients receiving iodixanol (Visipaque) 320mg I/ml reported less discomfort, characterized by heat or cold sensation or pain upon injection, than patients receiving iopamidol (Isovue) 370 mg I/ml during peripheral arteriography. As with other iodinated contrast agents, iodixanol is often associated with sensations of discomfort, warmth or pain. The data were presented at the American College of Cardiology’s 63rd Annual Scientific Session and Expo.

“Contrast-induced discomfort is commonly seen in patients undergoing peripheral arteriography,” said Thomas Todoran, M.D., lead author of the study and assistant professor of medicine, director of vascular medicine at Medical University of South Carolina. “Patient discomfort continues to be a challenge, primarily because of potential for body movement that may lead to image degradation. Results from this study showed that Visipaque use led to significantly less patient discomfort, heat or pain when compared to Isovue. The results of this comparative study suggest that Visipaque may be a preferable contrast agent for use in peripheral arteriography.”

While this study was not powered to detect a difference in image quality, the number of subjects with image quality rated as excellent was numerically greater in the Visipaque group (86.5%) versus the Isovue group (82.4%), but the difference was not statistically significant. Discomfort impacted image quality in 6.5% of Isovue subject images and in 3.2% of Visipaque subject images.

For more information: www.newsroom.gehealthcare.com

Related Content

News | Cardiac Diagnostics| February 17, 2017
Levels of a protein in the blood associated with heart disease are also linked to early-stage brain damage, according...
Mercator MedSystems, DANCE trial data, ISET, LINC, Bullfrog Micro-Infusion Device
News | Peripheral Arterial Disease (PAD)| February 15, 2017
Mercator MedSystems announced that the national co-principal investigators of the company’s DANCE trial each presented...
Medtronic, IDE approval, IN.PACT Admiral drug-coated balloon, DCB, end-stage renal disease
News | Drug-Eluting Balloons| February 08, 2017
Medtronic plc announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug Administration...
CSI, LIBERTY 360 Study, ISET 2017, six-month data, lower extremity PAD
News | Atherectomy Devices| February 08, 2017
February 8, 2017 — Cardiovascular Systems (CSI) presented six-month data from its LIBERTY 360° post-market study in a
Penn Medicine, heart failure causes, YAP and TAZ proteins, Journal of Clinical Investigation study
News | Heart Failure| February 07, 2017
February 7, 2017 — Of the more than 700,000 Americans who suffer a heart attack each year, about a quarter go on to d
Avinger, VISION Study, two-year outcomes, LINC, Lumivascular technology, Pantheris, OCT-guided atherectomy
News | Atherectomy Devices| February 03, 2017
Avinger Inc. recently announced positive two-year clinical data from the pivotal VISION study of the company’s...
Texas Heart Institute, ischemic heart failure, adult stem cell therapy, CONCERT-HF clinical trial
News | Stem Cell Therapies| February 03, 2017
Physicians and researchers at Texas Heart Institute are recruiting patients who suffer from heart failure to...
Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication
Technology | Contrast Media| February 02, 2017
Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity...
Ohio State, Wexner Medical Center, keeping human hearts alive, track abnormal beats, reanimate, Vadim Fedorov

Part of a donated human heart is reanimated and recorded with four high-definition optic cameras in a laboratory at The Ohio State University Wexner Medical Center. Researchers keep the heart tissue alive to look for the causes of irregular heartbeats in cases of persistent atrial fibrillation. Image courtesy of The Ohio State University Wexner Medical Center.

News | EP Lab| February 01, 2017
Researchers have developed a technique that allows them to revive parts of human hearts in the laboratory for up to 12...
CT, computed tomography, IV contrast media, acute kidney injury risk, Annals of Emergency Medicine study

A new study in Annals of Emergency Medicine finds no association between intravenous contrast media used in computed tomography (CT) and kidney damage. Roughly 80 million doses of IV contrast media are given every year. Credit: American College of Emergency Physicians

News | Contrast Media| January 30, 2017
Intravenous contrast media (typically iohexol or iodixanol) used in computed tomography (CT) does not appear to be...
Overlay Init